Related Experiment Videos
Angiotensin-converting enzyme inhibitor-induced angioedema: still unrecognized
C J Finley1, M A Silverman, A E Nunez
1Department of Emergency Medicine, Eastern Virginia Graduate School of Medicine, Norfolk 23507.
The American Journal of Emergency Medicine
|November 1, 1992
Summary
Angiotensin-converting enzyme inhibitor-induced angioedema is a rare but serious side effect. Misdiagnosis is common in emergency departments, delaying appropriate treatment for this condition.
Area of Science:
- Cardiology
- Pharmacology
- Emergency Medicine
Background:
- Angiotensin-converting enzyme inhibitors (ACEIs) are a cornerstone of hypertension management.
- While generally safe, ACEIs carry a 0.1% to 0.2% risk of angioedema, a potentially life-threatening adverse effect.
Observation:
- Angioedema typically affects the head and neck, including the face, lips, tongue, and glottis.
- A case study highlights a patient experiencing 18 episodes of angioedema over 3 years before diagnosis.
- Initial treatments often involve standard anti-allergic therapies, which may be insufficient.
Findings:
- Delayed diagnosis of ACEI-induced angioedema is a significant concern.
- Emergency physicians may lack familiarity with this adverse effect despite existing literature.
Implications:
- Increased awareness and diagnostic vigilance for ACEI-induced angioedema in emergency settings are crucial.
- Prompt recognition can prevent recurrent episodes and guide appropriate, potentially more aggressive, therapeutic interventions.
- This highlights a gap in physician education regarding common, yet severe, medication side effects.